List of Excipients in Branded Drug CLINDAMYCIN PHOSPHATE AND TRETINION

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	CLINDAMYCIN PHOSPHATE AND TRETINION	clindamycin phosphate and tretinoin	66993-959	ANHYDROUS CITRIC ACID
Prasco Laboratories	CLINDAMYCIN PHOSPHATE AND TRETINION	clindamycin phosphate and tretinoin	66993-959	BUTYLATED HYDROXYTOLUENE
Prasco Laboratories	CLINDAMYCIN PHOSPHATE AND TRETINION	clindamycin phosphate and tretinoin	66993-959	CARBOMER HOMOPOLYMER TYPE C

Clindamycin Phosphate and Tretinoin Excipient Strategy and Commercial Opportunities

Last updated: October 22, 2026

Clindamycin phosphate/tretinoin is a prescription topical acne combination with a mature active-ingredient profile and limited room for differentiation through new molecular claims. The strongest commercial opportunities are in excipient-controlled delivery, improved tolerability, preservative reduction, lower-cost manufacturing, and differentiated generic or private-label products. The reference combination, marketed as Ziana Gel, contains clindamycin phosphate equivalent to 1.2% clindamycin and tretinoin 0.025% in an aqueous gel vehicle.[1]

What is the FDA status of clindamycin phosphate and tretinoin?

Clindamycin phosphate/tretinoin topical gel is FDA-approved for acne vulgaris in patients at least 12 years old. The combination uses two established acne actives with complementary pharmacology:

• Clindamycin is a topical lincosamide antibiotic.
• Tretinoin is a retinoid that normalizes follicular keratinization and promotes comedolysis.
• The combination targets inflammatory and non-inflammatory acne lesions.

The reference product, Ziana Gel, was approved in 2006 under NDA 050756. Veltin, another branded clindamycin phosphate/tretinoin gel, was also approved as a prescription acne product. Generic products have entered the U.S. market through abbreviated new drug applications.

What dosage form is commercially established?

The established dosage form is a topical aqueous gel containing:

Attribute	Reference product profile
Clindamycin phosphate	1.2%, equivalent to 1% clindamycin
Tretinoin	0.025%
Route	Topical
Indication	Acne vulgaris
Patient population	Patients 12 years and older
Vehicle	Aqueous polymeric gel
Application	Once daily
Regulatory pathway	NDA and ANDA pathways

The product is not a biologic and has no biosimilar pathway. Competitive risk comes from generic topical products, alternative retinoid combinations, fixed-dose acne products, and over-the-counter benzoyl peroxide and adapalene products.

What excipients are used in clindamycin phosphate and tretinoin gel?

The Ziana formulation uses a relatively simple excipient system consisting of purified water, glycerin, carbomer 934P, methylparaben, polysorbate 80, and tromethamine.[1] Each excipient has a defined technical role.

Excipient	Primary function	Commercial relevance
Purified water	Continuous phase	Controls viscosity, microbial risk, and manufacturing cost
Carbomer 934P	Gelling and rheology agent	Controls spreadability, residence time, and suspension behavior
Glycerin	Humectant and solvent aid	Supports skin hydration and may reduce retinoid-related dryness
Polysorbate 80	Solubilizer and wetting agent	Helps distribute tretinoin and improve uniformity
Tromethamine	pH adjuster and neutralizer	Builds carbomer viscosity and controls active stability
Methylparaben	Preservative	Protects the aqueous gel against microbial growth

The excipient strategy must balance four competing requirements: tretinoin photochemical stability, clindamycin phosphate stability, acceptable skin feel, and microbiological protection.

How should excipients be selected for formulation development?

Excipient selection should begin with the active ingredients rather than with the preferred vehicle.

Tretinoin stability

Tretinoin is sensitive to light, oxygen, heat, and formulation environment. The formulation should minimize exposure to ultraviolet light and oxygen during manufacture, filling, storage, and use. Key controls include:

• Opaque or light-protective packaging.
• Low headspace oxygen.
• Controlled manufacturing temperature.
• Protection from prolonged exposure to elevated temperature.
• Compatibility screening for surfactants, polymers, and preservatives.
• Stability testing under ICH long-term, accelerated, and photostability conditions.

Polysorbate 80 can improve wetting and dispersion, but surfactant concentration should be optimized because excess surfactant can affect skin tolerability and may alter degradation behavior.

Clindamycin phosphate compatibility

Clindamycin phosphate is water-soluble and is suitable for an aqueous gel. The principal formulation risks are pH drift, hydrolysis, microbial contamination, and interaction with the polymer or preservative system.

The pH must support both active-ingredient stability and acceptable skin tolerability. Strongly acidic or alkaline conditions can increase irritation or destabilize one or both actives. Tromethamine is useful because it neutralizes carbomer and permits viscosity development without requiring a highly alkaline formulation.

Rheology and application performance

Carbomer 934P provides a familiar gel structure, but alternative polymers may create differentiation:

• Acrylates/C10-30 alkyl acrylate crosspolymer can produce a lighter, less tacky gel.
• Hydroxyethylcellulose can provide a softer gel with different spreadability.
• Poloxamers can support thermoresponsive or enhanced-rheology systems.
• Cellulose derivatives may support preservative-reduced formulations, subject to microbial validation.
• Polyacrylate-based systems may improve suspension and reduce phase separation.

A higher-yield commercial formulation is not necessarily the most viscous formulation. Acne patients often apply topical products over broad facial areas. Fast spreading, low pilling, low residue, and compatibility with cosmetics can improve adherence.

What formulation patents protect clindamycin phosphate and tretinoin?

The historical patent estate for the combination centered on fixed-dose topical compositions containing clindamycin or clindamycin phosphate with tretinoin. Patent protection for the original U.S. branded products has largely matured, and generic competition has reduced the value of broad composition claims.

The commercially relevant protection categories are:

1. Fixed-dose clindamycin phosphate/tretinoin compositions.
2. Specific polymeric gel systems.
3. Stabilized tretinoin formulations.
4. Methods of treating acne with the combination.
5. Packaging and storage configurations that reduce light or oxygen exposure.
6. Manufacturing methods that improve active uniformity or stability.

The FDA Orange Book remains the controlling source for current listed patents and exclusivity information for approved reference products.[2] Patent status must be reviewed separately for each NDA and jurisdiction because Orange Book listings, patent expiration, pediatric exclusivity, and product discontinuation status can differ.

Are method-of-use patents commercially important?

Method-of-use claims may cover treatment of acne with once-daily administration or defined patient groups. Their practical value is limited when:

• The indication is already established.
• Generic labeling uses a permissible section viii carve-out.
• The method claim does not create a meaningful prescribing distinction.
• Physicians use the drug for the same indication independent of the branded label.

Method-of-use protection is more valuable when linked to a differentiated concentration, dosing frequency, tolerability profile, or patient population that a generic competitor cannot easily omit from its label.

When does clindamycin phosphate and tretinoin lose exclusivity?

The key U.S. exclusivity events occurred years after the original approvals. The relevant commercial issue is no longer basic market entry protection but the durability of residual patents, formulation distinctions, and regulatory barriers.

Exclusivity category	Strategic relevance
New chemical entity exclusivity	Does not apply to this established combination
New drug product exclusivity	Historical relevance for the original NDA
Pediatric exclusivity	Must be checked against the listed NDA and approval history
Orange Book patents	Potential barrier to an ANDA if still listed and enforceable
Formulation patents	May support differentiated follow-on products
Method-of-use patents	May affect labeling strategy and litigation exposure
Data exclusivity	Generally limited for an old combination product

A generic applicant can challenge listed patents through Paragraph IV certification. A Paragraph IV notice can trigger patent litigation and, depending on the timing and statutory conditions, a 30-month stay of FDA approval under the Hatch-Waxman framework.[3]

What Paragraph IV challenges and litigation affect the product?

The principal U.S. litigation risk is associated with ANDA filings directed to the reference gel or a listed formulation. The commercial significance of a challenge depends on:

• The number and scope of Orange Book patents.
• Whether the challenger certifies Paragraph IV or uses a section viii statement.
• Whether the NDA holder files suit within 45 days.
• Whether the patents cover the active combination or only a narrow vehicle.
• Whether the challenger can launch at risk after patent expiry or settlement.

For a mature topical product, litigation is often less attractive than for a high-revenue oral drug because market share can fragment across several generic entrants. The economic value of a settlement depends on remaining patent life and the number of potential entrants.

What excipient opportunities exist for new products?

Preservative-reduced and preservative-free gels

Methylparaben is effective and familiar, but some patients associate preservatives with irritation. A preservative-reduced or preservative-free multidose system could support premium positioning if the package and microbiological controls are robust.

Potential approaches include:

• Airless pump packaging.
• Unit-dose sachets.
• Metered-dose dispensers.
• Lower-water-activity systems.
• Improved container-closure integrity.
• Polymer systems with validated antimicrobial protection.

The key regulatory burden is preservative effectiveness, in-use stability, microbial limits, and container-closure validation.

Lower-irritancy vehicles

Tretinoin commonly causes erythema, peeling, dryness, and burning. A vehicle that improves tolerability can create commercial differentiation even without changing the active concentrations.

Candidate strategies include:

• Humectant optimization using glycerin, propylene glycol, or glycols.
• Reduced surfactant loading.
• Emollient-containing aqueous gels.
• Controlled-release polymer networks.
• Lipid or microemulsion systems.
• Skin-barrier-supportive excipients such as selected ceramides or fatty alcohols.

Any excipient that changes tretinoin release, penetration, or exposure may require comparative clinical or pharmacokinetic evidence. Cosmetic claims cannot substitute for FDA-supported therapeutic claims.

Foam, cream, and emulsion dosage forms

A cream or emulsion can target patients who find gels drying. A foam may improve spreadability and reduce residue. Both dosage forms create technical challenges:

• Tretinoin must remain uniformly distributed.
• Clindamycin phosphate must remain compatible with the aqueous phase.
• Emulsion droplet size must remain stable.
• Propellant and package compatibility must be demonstrated for foams.
• In-use dosing must be reproducible.

These products may qualify as 505(b)(2) products or require a more complex regulatory strategy, depending on the formulation changes and comparative data package.[4]

How strong is the patent estate for a new excipient platform?

A new excipient platform can be stronger than a simple generic if it claims measurable technical advantages. Stronger claim categories include:

• A defined polymer and neutralizer ratio.
• A specified particle-size distribution for tretinoin.
• A defined oxygen or light-protection package.
• A stability profile at elevated temperature.
• A controlled-release or reduced-irritation delivery system.
• A preservative-free multidose container with validated microbiological performance.
• A specific combination of humectants and rheology modifiers that improves active retention or patient tolerability.

Weak claims include broad lists of conventional excipients, routine pH adjustment, or simple substitution of one carbomer grade for another without unexpected results.

Patent filings should include comparative data against the reference gel. Useful data sets include assay, degradation products, viscosity, particle size, rheology, photostability, in-use stability, skin irritation, and patient preference.

What commercial opportunities exist for manufacturers and licensors?

The most practical opportunities are:

Opportunity	Commercial model	Main barrier
Low-cost generic gel	ANDA launch	Price erosion and crowded market
Premium low-irritancy gel	505(b)(2) or NDA strategy	Clinical and comparative evidence
Preservative-free product	Specialty dermatology	Package and microbiology validation
Private-label dermatology product	Contract manufacturing	Brand support and supply reliability
Regional licensing	Territory-based commercialization	Local registration and channel access
Combination product for adherence	Branded or specialty product	Differentiation against established generics
Improved packaging	Device or formulation patent	Human factors and compatibility data

A licensing deal is most attractive when the formulation has a clear advantage, such as longer room-temperature stability, reduced irritation, improved cosmetic acceptability, or a package that supports adherence. A conventional gel with no clinical or manufacturing advantage is unlikely to command meaningful licensing value.

How does this product compare with competing acne therapies?

Product category	Main advantage	Main limitation
Clindamycin/tretinoin	Combines antibiotic and retinoid activity	Antibiotic-resistance and irritation concerns
Adapalene/benzoyl peroxide	Strong non-antibiotic combination	May cause dryness and bleaching of fabrics
Tretinoin alone	Broad retinoid use and multiple strengths	Irritation and slower patient acceptance
Clindamycin/benzoyl peroxide	Anti-inflammatory and antibacterial activity	Dryness, odor, and bleaching
Tazarotene products	Potent retinoid activity	Higher irritation potential
Over-the-counter adapalene	Low access barrier and low cost	Less formulation and strength differentiation

Antibiotic stewardship reduces the long-term attractiveness of clindamycin-containing products. A commercial strategy should emphasize limited-duration use, combination therapy, and adherence rather than antibiotic positioning alone.[5]

Key Takeaways

• The reference formulation is an aqueous carbomer gel containing clindamycin phosphate, tretinoin, glycerin, polysorbate 80, methylparaben, tromethamine, and purified water.
• Broad composition protection for the original combination is mature; new value depends on formulation, packaging, tolerability, and manufacturing claims.
• Tretinoin photostability and skin irritation are the central formulation problems.
• Carbomer, pH control, surfactant selection, and oxygen/light protection require integrated optimization.
• Preservative-reduced systems, airless packaging, controlled-release gels, and lower-irritancy vehicles offer the clearest commercial opportunities.
• Paragraph IV risk is relevant for any remaining Orange Book-listed patents, but mature topical markets generally face rapid price erosion after multiple generic launches.
• The strongest new patent positions will require comparative stability, delivery, tolerability, or in-use performance data.
• Antibiotic-resistance concerns limit the long-term strategic value of clindamycin unless the product improves adherence or reduces irritation.

FAQs About Clindamycin Phosphate and Tretinoin Excipient Strategy

Can benzoyl peroxide be added to clindamycin phosphate and tretinoin gel?

Yes, but the combination creates a different formulation and regulatory product. Benzoyl peroxide can improve antibiotic stewardship by reducing bacterial resistance, but it introduces stability, discoloration, irritation, and packaging challenges.

Is a preservative-free clindamycin/tretinoin gel feasible?

Yes, but feasibility depends on the package, water activity, manufacturing controls, and in-use microbiological performance. A conventional multidose jar is less suitable than an airless pump or unit-dose system.

Which polymer is best for a tretinoin gel?

Carbomer is commercially established, but no polymer is universally optimal. The best choice depends on viscosity, spreadability, active uniformity, pH, photostability, skin feel, and preservative compatibility.

Does changing the excipient system create a new patent opportunity?

It can. Patent value is strongest when the new excipient system produces an unexpected and measurable result, such as improved tretinoin stability, reduced irritation, longer in-use shelf life, or controlled release.

Is clindamycin phosphate/tretinoin suitable for a 505(b)(2) product?

A substantially changed dosage form, delivery system, concentration, or clinical use may support a 505(b)(2) strategy. The regulatory pathway depends on the extent of formulation change and the data needed to bridge the new product to the reference product.

References

1. U.S. Food and Drug Administration. (2006). Ziana (clindamycin phosphate and tretinoin) gel prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).
5. American Academy of Dermatology Association. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.